#2
Regeneron Pharmaceuticals
The $100B market cap biotech with $13B revenue powered by Dupixent, the blockbuster eczema and asthma drug heading for $12B+ peak sales. Regeneron's antibody platform also produced world-class eye disease and cancer treatments, with Eylea generating $5.8B in sales.
Photos (1)
Comments on "Regeneron Pharmaceuticals"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.